IP Library Patent Application 11978519
Patent Application
App. No. 11/978,519

HLA binding motifs and peptides and their uses

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
11/978,519
Abstract

The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles and inducing T cell activation in T cells restricted by the allele. The peptides are useful to elicit an immune response against a desired antigen.

Claims (16)

1 . (canceled)

2 . A peptide selected from the group consisting of peptides found in Tables 2-189.

3 . An isolated peptide less than 15 amino acids in length comprising the oligopeptide LLTFWNPPV (SEQ ID NO:11419).

4 . A composition comprising the peptide of claim 3 , wherein said peptide is linked to a T helper peptide.

5 . A composition comprising the peptide of claim 3 , wherein said peptide is linked to a spacer or linker, wherein said spacer or linker is between one and six amino acids in length.

6 . A composition comprising the peptide of claim 3 , wherein said peptide is linked to a carrier.

7 . A composition comprising the peptide of claim 3 , wherein said peptide is linked to a lipid.

8 . A composition comprising the peptide of claim 4 , wherein said T-helper peptide is the PADRE helper peptide having the sequence aKXVAAWTLKAAa (SEQ ID NO:14635), wherein a is d-alanine and X is cyclohexylalanine.

9 . A homopolymer of the peptide of claim 3 .

10 . A heteropolymer of the peptide of claim 3 and at least one different peptide, wherein said at least one different peptide is not derived from influenza and is a cytotoxic T cell (CTL)-inducing peptide or a helper T cell (HTL)-inducing peptide.

11 . A composition comprising the peptide of claim 3 and a carrier.

12 . A composition comprising the peptide of claim 3 and a pharmaceutically acceptable excipient.

13 . A composition comprising the peptide of claim 3 and a liposome.

14 . A composition comprising the peptide of claim 3 , and one or more different isolated peptides, wherein said one or more different isolated peptides is selected from the group consisting of: a cytotoxic T cell (CTL)-inducing peptide and a helper T cell (HTL)-inducing peptide.

15 . The composition of claim 14 , further comprising a carrier.

16 . The composition of claim 14 further comprising a pharmaceutically acceptable excipient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: IDM PHARMA, INC.
To: BIOTECH SYNERGY, INC.
Reel/Frame 033453/0170 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 31, 2014
From: BIOTECH SYNERGY, INC.
To: OSE PHARMA INTERNATIONAL SA
Reel/Frame 033453/0211 →